替加环素联合方案治疗ICU内CR-GNB院内肺炎的临床疗效:一项回顾性多中心观察性研究
该多中心回顾性队列研究纳入395例ICU内CR-GNB院内肺炎患者,148例接受替加环素联合至少一种抗CR-GNB药物,247例未用替加环素,超过80%为CRAB感染。原始队列中替加环素组28天全因死亡率27.7% vs 36.0%(p=0.088),差异未达统计学显著;倾向评分匹配队列(102对)中,替加环素组临床失败率显著更低(46.1% vs 62.7%,p=0.017),28天死亡率显著更低(28.4% vs 52.9%,p<0.001)。多因素分析显示替加环素是临床失败(PS匹配队列aOR 0.52,95%CI 0.28-0.95)和28天全因死亡(原始队列aHR 0.69,95%CI 0.47-0.99;PS匹配队列aHR 0.47,95%CI 0.30-0.74)的保护因素。亚组Kaplan-Meier分析提示替加环素加入含黏菌素(log rank p=0.005)和含碳青霉烯类(log rank p=0.007)联合方案时有显著临床获益。
要点
- 在ICU因CR-GNB(>80%为CRAB)院内肺炎患者中,联合方案加用替加环素与PS匹配队列28天死亡率显著降低相关(28.4% vs 52.9%,p<0.001)。
- PS匹配队列中替加环素组临床失败率显著低于未用组(46.1% vs 62.7%,p=0.017)。
- 原始队列28天全因死亡率替加环素组27.7% vs 未用组36.0%,差异未达统计学显著(p=0.088)。
- 多因素分析中替加环素为28天全因死亡保护因素:原始队列aHR 0.69(95%CI 0.47-0.99),PS匹配队列aHR 0.47(95%CI 0.30-0.74)。
- 亚组分析提示替加环素加入含黏菌素(log rank p=0.005)或含碳青霉烯类(log rank p=0.007)联合方案时临床获益显著。
适用人群与场景
- ICU收治的院内肺炎患者,病原为替加环素敏感的CR-GNB,其中超过80%为CR-Acinetobacter baumannii(CRAB)。
研究设计与关键结果
- 多中心回顾性队列研究,纳入395例ICU内CR-GNB院内肺炎患者,148例接受替加环素联合至少一种抗CR-GNB药物,247例未用替加环素;超过80%为CRAB感染。
- 原始队列28天全因死亡率:替加环素组27.7% vs 未用组36.0%(p=0.088),差异未达统计学显著。
- 倾向评分匹配队列(102对):替加环素组临床失败率46.1% vs 未用组62.7%(p=0.017),28天死亡率28.4% vs 52.9%(p<0.001)。
- 多因素分析:替加环素治疗为临床失败保护因素(PS匹配队列aOR 0.52,95%CI 0.28-0.95),为28天全因死亡保护因素(原始队列aHR 0.69,95%CI 0.47-0.99;PS匹配队列aHR 0.47,95%CI 0.30-0.74)。
- 亚组Kaplan-Meier生存分析提示替加环素加入含黏菌素联合方案(log rank p=0.005)和含碳青霉烯类联合方案(log rank p=0.007)时有显著临床获益。
证据类型、等级与局限
- 证据类型:回顾性多中心观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在替加环素敏感的CR-GNB(多为CRAB)所致ICU院内肺炎中,替加环素作为联合治疗方案的一部分与较低的临床失败率和全因死亡率相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tigecycline has in vitro bacteriostatic activity against a broad spectrum of bacteria, including carbapenem-resistant Gram-negative bacteria (CR-GNB). However, the role of tigecycline in treatment of nosocomial pneumonia caused by CR-GNB remains controversial and clinical evidences are limited. We aimed to investigate the clinical benefits of tigecycline as part of the combination treatment of nosocomial CR-GNB pneumonia in intensive care unit (ICU).
METHODS: This multi-centre cohort study retrospectively enrolled ICU-admitted patients with nosocomial pneumonia caused by CR-GNB. Patients were categorized based on whether add-on tigecycline was used in combination with at least one anti-CR-GNB antibiotic. Clinical outcomes and all-cause mortality between patients with and without tigecycline were compared in the original and propensity score (PS)-matched cohorts. A subgroup analysis was also performed to explore the differences of clinical efficacies of add-on tigecycline treatment when combined with various anti-CR-GNB agents.
RESULTS: We analysed 395 patients with CR-GNB nosocomial pneumonia, of whom 148 received tigecycline and 247 did not. More than 80% of the enrolled patients were infected by CR-Acinetobacter baumannii (CRAB). A trend of lower all-cause mortality on day 28 was noted in tigecycline group in the original cohort (27.7% vs. 36.0%, p = 0.088). In PS-matched cohort (102 patient pairs), patients with tigecycline had significantly lower clinical failure (46.1% vs. 62.7%, p = 0.017) and mortality rates (28.4% vs. 52.9%, p < 0.001) on day 28. In multivariate analysis, tigecycline treatment was a protective factor against clinical failure (PS-matched cohort: aOR 0.52, 95% CI 0.28-0.95) and all-cause mortality (original cohort: aHR 0.69, 95% CI 0.47-0.99; PS-matched cohort: aHR 0.47, 95% CI 0.30-0.74) at 28 days. Kaplan-Meier survival analysis in subgroups of patients suggested significant clinical benefits of tigecycline when added to a colistin-included (log rank p value 0.005) and carbapenem-included (log rank p value 0.007) combination regimen.
CONCLUSIONS: In this retrospective observational study that included ICU-admitted patients with nosocomial pneumonia caused by tigecycline-susceptible CR-GNB, mostly CRAB, tigecycline as part of a combination treatment regimen was associated with lower clinical failure and all-cause mortality rates.
参考来源
- Yang KY, Peng CK, Sheu CC, et al. Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study. J Intensive Care. 2023. PMID: 36597165. doi:10.1186/s40560-022-00647-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。